FTO and neoplasm: Another 2 molecules, CS1 and CS2, have been screened out and identified as effective inhibitors of FTO, which can suppress its m6A demethylase activity by occupying the catalytic pocket and interfering with the binding of FTO with m6A-modified RNAs and then exert potent anti-leukemic efficacy in vivo and in vitro.80 The potent anti-tumor efficacy and minimal side effects of CS1 and CS2 suggest that they are highly feasible for clinical application.